{"body": "The company announced its last quarter financial performance results on 10/19/2016. Abbott Laboratories (NYSE:ABT) belongs to Medical sector that declined -0.07% in value when last trading session closed at $40.31. The company has a market capitalization of $69.48 Billion. The company’s stock has a Return on Assets (ROA) of 3.4 percent, a Return on Equity (ROE) of 6.6 percent and Return on Investment (ROI) of 7.7 percent. The company reached its 52-Week high of $45.79 on Aug 2, 2016 and 52-Week low of $36 on Jan 28, 2016.\n\nEarnings per share (ttm) for Abbott Laboratories (NYSE:ABT) according to Finviz Data is $0.67.\n\nThe growth estimate for Abbott Laboratories (NYSE:ABT) for the current quarter is 4.8 percent. The projected growth estimate for the next quarter is 22 percent. The company’s stock has grown by -17.27 percent in the past 5 years. For the next 5 years, the company is expected to grow by 10.14 percent.\n\nThis company was Upgrade by Edward Jones on 21-Jun-16  to Buy.\n\nThe 14 analysts offering 12-month price forecasts for Abbott Laboratories have a median target of 47.50, with a high estimate of 50.00 and a low estimate of 41.00. The median estimate represents a +17.84% increase from the last price of 40.31.\n\nFollowing Earnings result, share price were DOWN 15 times out of last 28 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 91% percent of times. It has met expectations  1 times and missed earnings  0 times.\n\nThe consensus recommendation for Abbott Laboratories (NYSE:ABT) is 1.6. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.6. In comparison, the consensus recommendation 60 days ago was at 1.6, and 90 days ago was at 1.6 respectively.\n\nWhen the current quarter ends, Wall Street expects Abbott Laboratories to have earnings per share of $0.65.\n\nRevenue is expected to range from 5.29 Billion to 5.45 Billion with an average of 5.38 Billion.\n\nAbbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare.  They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.\n\nNetflix, Inc. (NASDAQ:NFLX) belongs to Consumer Discretionary sector closed its last session with a gain of 1.98 percent and closed its previous trading session at $140.11. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $0.43. The company has the Market capitalization of $60.05 Billion. The company’s stock has a Return on Assets (ROA) of 1.5 percent, a Return on Equity (ROE) of 7.5 percent and Return on Investment (ROI) of 5.1 percent. The company reached its 52-Week high of $143.46 on Jan 19, 2017 and 52-Week low of $79.95 on Feb 8, 2016.\n\nThe growth estimate for Netflix, Inc. (NASDAQ:NFLX) for the current quarter is 500 percent. The projected growth estimate for the next quarter is 155.6 percent. The company’s stock has grown by 15.06 percent in the past 5 years. For the next 5 years, the company is expected to grow by 80 percent.\n\nThis company was Upgrade by Macquarie on 19-Jan-17 to Neutral.\n\nThe 37 analysts offering 12-month price forecasts for Netflix have a median target of 135.00, with a high estimate of 165.00 and a low estimate of 60.00. The median estimate represents a -3.65% decrease from the last price of 140.11.\n\nFollowing Earnings result, share price were DOWN 15 times out of last 28 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 75% percent of times. It has met expectations  3  times and missed earnings  0 times.\n\nThe consensus recommendation for Netflix, Inc. (NASDAQ:NFLX) is 2.13. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.31. In comparison, the consensus recommendation 60 days ago was at 2.35, and 90 days ago was at 2.27 respectively.\n\nWhen the current quarter ends, Wall Street expects Netflix, Inc. to have earnings per share of $0.36.\n\nRevenue is expected to range from 2.59 Billion to 2.71 Billion with an average of 2.64 Billion.\n\nNetflix is the world’s leading Internet television network with millions of subscribers in nearly 50 countries who have access to an ever-expanding library of TV shows and movies, including original programming, documentaries and feature films. The company offers the ability to watch as subscribers want, anytime, anywhere, on nearly any Internet-connected screen.", "category": "Netflix", "title": "Stocks Buzz: Abbott Laboratories (NYSE:ABT), Netflix, Inc. (NASDAQ:NFLX)"}